<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904852</url>
  </required_header>
  <id_info>
    <org_study_id>C03003</org_study_id>
    <nct_id>NCT00904852</nct_id>
  </id_info>
  <brief_title>Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Tandutinib (Formerly MLN518) in Combination With Temozolomide and Bevacizumab Following Concurrent Radiation Therapy and Temozolomide in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety study of tandutinib in combination with temozolomide and bevacizumab after
      people have received radiation therapy and temozolomide treatment. This study will determine
      the maximum safe dose of tandutinib when combined with temozolomide and bevacizumab and
      evaluate the safety of the combination treatment.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of tandutinib, adverse events, serious adverse events and dose limiting toxicities, clinical laboratory values and vital sign measurements</measure>
    <time_frame>Cycle 1 days 1, 8, 15, and 22. Cycle 2 -6 days 1 and 15</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Tandutinib, bevacizumab, and temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tandutinib, bevacizumab, and temozolomide</intervention_name>
    <description>All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle</description>
    <arm_group_label>Tandutinib, bevacizumab, and temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of glioblastoma multiforme

          -  Received radiotherapy for glioblastoma multiforme

          -  Patients who have not had previous treatments for glioblastoma multiforme (except for
             surgery, radiation and temozolomide therapy)

          -  Females that are postmenopausal for at least 1 year prior to screening visit

          -  18 years of age and older

        Exclusion Criteria:

          -  Other brain cancers that are not diagnosed as glioblastoma multiforme

          -  female patients who are lactating or are pregnant

          -  HIV positive and/or any other active infection requiring therapy

          -  Known hepatitis B or hepatitis C infection

          -  Diagnosed or treated any other cancer within 2 years before the first dose

          -  History of cardiovascular conditions and/or vascular disease

          -  Allergic to any component of bevacizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudha Parasuraman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>May 19, 2009</last_update_submitted>
  <last_update_submitted_qc>May 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Anthony Boral, Vice President Clinical Research</name_title>
    <organization>Millennium Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

